Reid Merryman, MD, on Pre- and Post-Transplant Data for Patients with DLBCL

Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, of the Dana-Farber Cancer Institute, spoke with CancerNetwork® about the significance of dividing cohorts of patients with diffuse large B-cell lymphoma (DLBCL) into by pre- and post-transplantation groups and the questions that need to be asked from an oral presentation at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.

Transcription:

So, I think it’s kind of 2 different questions. Looking at samples before transplant, you’re asking, “could we use information that we have to determine if transplant is the right treatment approach for patients?” And [What’s] different from 5 or 10 years ago, I think [is that] we have novel treatments. The obvious one would be CAR [chimeric antigen receptor] T-cell therapies that could potentially be used with curative intent in this setting for patients who we think might do poorly with autologous stem cell transplant.

We’re asking a little bit of a different question for the serial samples after autologous stem cell transplant. In that setting, obviously, the patient has undergone transplantation. The question would be, “are there things that we could do in terms of maintenance or consolidation therapies that might improve outcomes for high-risk patients who are likely to relapse?”

Related Videos
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Related Content